Discover how rheumatoid arthritis advances through distinct stages, the symptoms at each phase, and treatment approaches that ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing -HAMPTON, N.J., ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.

a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis-thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell ...